メニュー 戻るClinical Trial Flexibility and Customization Needs that are Required by Biotechs and Next Generation Therapies

Clinical Trial Flexibility and Customization Needs that are Required by Biotechs and Next Generation Therapies


概要

Brought to you by DIA in cooperation with

MEDIDATA


COVID-19 has ushered in new challenges when conducting clinical trials, but mid-tier biotech companies have different needs then large pharmaceutical companies. When companies are conducting studies for therapeutic areas such as oncology, or are conducting clinical trials for next generation therapies, a smaller sponsor requires a partner that is nimble, fast acting and flexible, as well as transparent. Communicating what is required is vital, but even more important, having a partner that can communicate what is possible is key. This webinar will outline the 3 areas that mid-tier biotech companies need from CROs, which are people, process and technology.

特集トピック

  • A Sponsor’s perspective on the decision making criteria for selecting a CRO partners

  • Need for a niche CRO solution, based on the growth and increased complexities of oncology studies

  • Technology investments and capabilities that allow CROs to adapt to meet the unique needs of biotechs

学習目的

Upon completion of the webinar, participants will have a better understanding of:

  • Understand the unique needs of small and midsize biotech companies when conducting oncology studies
  • Recognize the need for an adaptive and responsive CRO amidst the current landscape and increased demand within the growing biotechnology industry
  • Learn CRO best practices for adapting to the specific needs of small and midsize biotechs
  • Tailor operational and technological approaches to planning, launching and conducting studies for a growing market

Continuing Education Credits are not available for this event.


お問い合わせ

REGISTRATION OR EVENT QUESTIONS?

Send Email

Zoom Technical Support

Send Email


WANT MORE VIRTUAL EVENTS?

View live and on demand solution provider webinars